Jennifer R. Grandis, MD, FACS
UPMC Endowed Chair in Head and Neck Cancer Surgical Research
Distinguished Professor of Otolaryngology and Pharmacology

Dr. Grandis is a member of the Cellular and Molecular Pathology Graduate Training Program. She is also the Vice Chair for Research in the Department of Otolaryngology, the Assistant Vice Chancellor for Research Program Integration in the Health Sciences and the Program Leader in the Head and Neck Cancer Program in the University of Pittsburgh Cancer Institute.
Office Location:
Eye & Ear Institute, Suite 500
203 Lothrop Street
Pittsburgh, PA 15213
Contact Information:
Office Telephone: 412-647-5280
Lab Telephone: 412-383-5405
Fax: 412-647-2080


  • BS - 1982, Swarthmore College
  • MD - 1987, University of Pittsburgh

Clinical Expertise

Otolaryngology with a focus on head and neck cancer

Research Interests

Dr. Grandis' current research efforts include the following:

1. Src Family Kinase Inhibitors- Src Family Kinase Inhibitors (e.g. dasatinib) are being tested in ongoing and planned clinical trials at UPCI in head and neck cancer patients. Ongoing projects in the lab are testing the hypothesis that activation of Src family kinases through both EGFR dependent and EGFR independent pathways contributes to SCCHN progression in the setting of EGFR blockade.

2. STAT3 as a Therapeutic Target- Evidence to date suggests that activation of Signal Transducer and Activator of Transcription 3 (STAT3) contributes to tumor growth, even in the setting of EGFR blockade. Ongoing studies are testing the hypothesis that STAT3 activation enhances SCCHN growth and contributes to resistance to therapies that target EGFR. New efforts are designed to use high throughput screens to identify small molecule inhibitors of STAT3. A STAT3 decoy oligonucleotide is also being designed as a therapeutic strategy.

3. EGFRvIII as a Therapeutic Target and Mediator of Clinical Resistance- The only alteration to date of EGFR identified in SCCHN tumors is the deletion variant, EGFRvIII, which mediates resistance to cetuximab by signaling through STAT3. Ongoing studies are testing the role of Src kinases in EGFRvIII signaling in SCCHN and developing a heterotopic xenograft model of EGFRvIII expressing tumors to test therapies.

4. Combined Molecular Targeting Approaches for SCCHN- Inhibition of a single pathway alone is unlikely to be beneficial for cancer treatment. We have access to a large number of small molecule inhibitors of critical signaling pathways that are in active clinical development. Ongoing studies are testing the effects of combining these inhibitors with anti-EGFR agents in preclinical SCCHN models to design rational therapeutic approaches.


Diplomate, American Board of Otolaryngology - 1994



Selected Publications

View Dr. Grandis' publications on PubMed

Sharafinski Jr ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010 Oct; 32(10):1412-21. PMID: 20848399. PMCID: PMC2946515.

Klein J, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biology & Therapy. 2010 Jan; 9(1): 1-7. Epub 2010 Jan 9. PMID: 20038820. PMCID: PMC3138532.

Kwok J, Langevin S, Argiris A, Gooding WE, Grandis JR, Taioli E. The impact of health insurance status on the survival of patients with head and neck cancer. Cancer. 2010 Jan 15; 116(2):476-85. PMID: 19937673. PMCID: PMC3085979.

Cassell A, Grandis JR. Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opinion On Investigational Drugs. 2010 Jun; 19(6): 709-22. PMID: 20415598. PMCID: PMC2947445.

Wheeler, SE, Suzuki S, Thomas SM, Sen M, Leeman-Neill RJ, Chiosea SI, Kuan CT, Bigner DD, Gooding WE, Lai SY, Grandis JR. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene. 2010 Sep 16; 29(37):5135-45. Epub 2010 Jul 12. PMID: 20622897. PMCID: PMC2940981.

Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clinical Cancer Research. 2010 May 1; 16(9): 2489-95. Epub 2010 Apr 20. PMID: 20406834. PMCID: PMC2887084.

Langevin SM, Stone RA, Bunker CH, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis. 2010 May; 31(5):864-70. Epub 2010 Mar 2. PMID: 20197299. PMCID: PMC2864416.

Feinstein TM, Lai SY, Lenzner D, Gooding WE, Ferris RL, Grandis JR, Myers EN, Johnson JT, Heron DE, Argiris A. Prognostic factors in patients with high-risk locally advanced salivary gland cancers treated with surgery and postoperative radiotherapy. Head Neck. 2011 Mar; 33(3): 318-23. doi: 10.1002/hed.21444. Epub 2011 Jan 31. PMID: 21284048. PMC Journal-not applicable.

Leeman-Neill RJ, Cai Q, Joyce SC, Thomas SM, Bhola NE, Neill DB, Arbiser JL, Grandis JR. Honokiol inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors. Clinical Cancer Research. 2010 May 1; 16(9): 2571-9. Epub 2010 Apr 13. PMID: 20388852. PMCID: PMC2871379.

Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion On Emerging Drugs. 2010 Sep; 15(3):355-73. PMID: 20557270. PMCID: PMC3133968.

Rwigema JCM, Heron DE, Ferris RL, Andrade RS, Gibson M, Yang Y, Ozhasoglu C, Argiris A, Grandis JR, Burton S. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent Squamous cell carcinoma of the head and neck treated stereotactic body radiation therapy. American Journal of Clinical Oncology. 2011 Aug; 34(4): 372-9. PMID: 20859194. PMCID: PMC3177149.

Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A. Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clinical Cancer Research. 2010 Apr 15; 16(8): 2427-34. PMID: 20371693. PMCID: PMC3030188.

Yang W, Cai Q, Lui VWY, Everley PA, Kim J, Bhola N, Quesnelle K, Zetter BR, Steen H, Freeman MR, Grandis JR. Quantitative proteomics analysis reveals molecular networks regulated by epidermal growth factor receptor level in head and neck cancer. Journal of Proteome Research. 2010 Jun 4; 9(6): 3073-82. PMID: 20426488. PMCID: PMC3149825.

Ostrow K, Hoque M, Loyo M, Brait M, Greenberg A, Siegfried J, Grandis J, Davis AG, Bigbee W, Rom W, Sidransky D. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation specific PCR. Clinical Cancer Research. 2010 Jul 1; 16(13): 3463-72. Epub 2010 Jun 30. PMID: 20592015. PMCID: PMC2899894.

Taoudi Benchekroun M, Saintigny P, Thomas SM, El-Naggar AK, Papadimitrakopoulou V, Ren H, Lang W, Fan Y, Huang J, Feng L, Lee JJ, Kim ES, Hong WK, Johnson FM, Grandis JR, Mao L. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prevention Research (Phila). 2010 Jul; 3(7): 800-9. Epub 2010 Jun 22. PMID: 20570883. PMCID: PMC2900459.

Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Bransetter BF, Posluszny DM, Wang L, Seethala RR, Dacic S, Gooding W, Grandis JR, Johnson JT, Ferris RL. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Journal of Clinical Oncol. 2010 Dec 20; 28(36): 5294-300. Epub 2010 Nov 15. PMID: 21079141. PMCID: PMC3018361.

Diergaarde B, Grandis JR. Human papilloma virus and head and neck cancer. Oncology (Williston Park). 2010 Sep; 24(10): 927, 933. PMID: 21138174. PMC Journal-not applicable.

Langevin SM, Stone RA, Bunker CH, Lyons-Weiler MA, LaFramboise WA, Kelly L, Seethala RR, Grandis JR, Sobol RW, Taioli E. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer. 2011 Apr 1; 117(7): 1454-62. doi: 10.1002/cncr.25689. Epub 2010 Nov 8. PMID: 21425146. PMCID: PMC3117118.

Ragin CC, Langevin SM, Marzouk M, Grandis J, Taioli E. Determinants of head and neck cancer survival by race. Head Neck. 2011 Aug; 33(8): 1092-8. Doi: 10.1002/hed.21584. Epub 2010 Oct 21. PMID: 20967872. PMCID: PMC3380362.

Sahu N, Grandis JR. New advances in molecular approaches to head and neck squamous cell carcinoma. Anti-Cancer Drugs. 2011 Aug; 22(7):656-64. PMID: 21178766. PMCID: PMC3080467.

Stabile LP, Dacic S, Land SR, Lenzner D, Dhir R, Aquafondata M, Landreneau RJ, Grandis JR, Siegfried JM. Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clinical Cancer Research. 2011 Jan 1; 17(1): 154-64. Epub 2010 Nov 9. PMID: 21062926. PMCID: PMC3064257.

Leeman-Neill RJ, Seethala RR, Singh SV, Freilino ML, Bednash JS, Thomas SM, Panahandeh MC, Gooding WE, Joyce SC, Lingen MW, Neill DB, Grandis JR. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prevention Research (Philadelphia, PA). 2011 Feb; 4(2): 230-7. Epub 2010 Dec 16. PMID: 21163936. PMCID: PMC3076320.

Egloff AM, Grandis JR. Response to combined molecular targeting: defining the role of p-STAT3. Clinical Cancer Research. 2011 Feb 1; 17(3): 393-5. Epub 2011 Jan 25. PMID: 21266530. PMCID: PMC3149866.

Argiris A, Karamouzis MV, Smith R, Kotsakis, Gibson MK, Lai SY, Kim S, Branstetter BF, Shuai Y, Romkes M, Wang L, Grandis JR, Ferris RL, Johnson JT, Heron DE. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Annals of Oncology 2011 Nov; 22(11): 2482-8. doi: 10.1093/annonc/mdr002. Epub 2011 Mar 1. PMID: 21363880. PMCID: PMC3200222.

Thomas SM, Grandis JR. Targeting mesenchymal exaptation to mitigate tumor growth. Cell Cycle. 2011 Aug 15; 10(16): 2626-7. Epub 2011 Aug 15. PMID: 21836394. PMC Journal-not applicable.

Langevin SM, Grandis JR, Taioli E. Female hormonal and reproductive factors and head and neck Squamous cell carcinoma risk. Cancer Letters. 2011 Nov 28; 310(2): 216-21. doi: 10.1016/j.canlet.2011.07.007. Epub 2011 Jul 12. PMID: 21802839. PMCID: PMC3169650.

Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clinical Cancer Research. 2011 Jul 1; 17(13): 4425-38. Epub 2011 May 27. PMID: 21622718. PMCID: PMC3138116.

Johnston PA, Grandis JR. STAT3 signaling: anticancer strategies and challenges. Molecular Intervention 2011 Feb; 11(1): 18-26. PMID: 21441118. PMCID: PMC3063716.

Ma H, Ziegler J, Li C, Sepulveda A, Bedeir A, Grandis JR, Lentzsch S, Mapara MY. Sequestial activation of inflammatory signaling pathways during graft-versus-host disease (GVHD): early role for STAT1 and STAT3. Cell Immunology. 2011; 268(1):37-46. PMID: 21376308. PMCID: PMC3061826.

Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A, Seethala R, Grandis JR. Targeting GPCR-mediated p70S6K activity may improve head and neck cancer response to cetuximab. Clinical Cancer Research. 2011 Aug 1; 17(15): 4996-5004. Epub 2011 Jun 8. PMID: 21653688. PMCID: PMC3149755.

Vaezi A, Wang XZ, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D’Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR. XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clinical Cancer Research. 2011 Aug 15; 17(16): 5513-22. DOI: 10.1158/1078-0432. CCR-11-0086. Epub 2011 Jul 7. PMID: 21737503. PMCID: PMC3156890.

Stransky N, Egloff AM, Tward A, Kostic A, Cibulskis K, Sivachenko A, Kryukov G, Lawrence M, Sougnez C, McKenna A, Ramos AH, Stojanov P, Carter SL, Voet D, Cortes M, Auclair D, Saksena G, Guiducci C, Onofrio R, Parkin M, Romkes M, Weissfeld J, Seethala RR, Wang L, Winckler W, Ardlie K, Gabriel SB, Myerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046): 1157-60. Epub 2011 Jul 28. PMID: 21798893. PMCID: PMC3415217.

Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clinical Cancer Research. 2011 Sep 15; 17(18): 5935-44. Epub 2011 Jul 26. PMID: 21791633. PMC Journal-In Process.

Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin N. Assembly And Initial Characterization Of A Panel Of 85 Genomically Validated Cell Lines From Diverse Head And Neck Tumor Sites. Clinical Cancer Research. 2011 Dec 1; 17(23): 7248-64. Epub 2011 Aug 25. PMID: 21868764. PMCID: PMC3229662.

Glazer P, Grandis JR, Powell S, Brown M, Helleday T, Bristow R, Powis G, Hill RP, Le TQ, Pelroy R, Mohla S, Bernhard EJ. Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities. Radiation Research. 2011 Sep; 176(3): e0016-21. Epub 2011 Jul 8. PMID: 21740251. PMC Journal-In Process.

Argiris A, Feinstein TM, Wang L, Yang T, Agrawal S, Appleman LJ, Stoller RG, Grandis JR, Egloff AM. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Investigational New Drugs. 2011 Sep 1. PMID: 21881918. PMCID: PMC3402509.

Zhong S, Nukui T, Buch S, Diergaarde B, Weissfeld LA, Grandis JR, Romkes M, Weissfeld JL. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent. Cancer, Epidemiology, Biomarkers & Prevention. 2011 Nov; 20(11): 2429-37. Epub 2011 Sep 2. doi: 10.1158/1055-9965.EPI-11-0520. PMID: 21890746. PMCID: PMC3210907.

Argiris A, Lee SC, Feinstein T, Thomas S, Branstetter BF 4th, Seethala R, Wang L, Gooding W, Grandis JR, Ferris RL. Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncology, 2011 Oct; 47(10): 961-6. Epub 2011 Sep 1. PMID: 21889392. PMCID: PMC3402506.

Park B, Chiosea S, Grandis JR. Molecular changes in the multistage pathogenesis of head and neck cancer. Cancer Biomarkers. 2011; 9(1-6): 325-39. PMID: 22112483. PMC3409637

Dedhia RC, Grandis JR, Fontes PA, Johnson JT, Weissfeld J. Screening for Head and Neck Cancer in Liver Transplant Candidates: A Review of 11 Years Experience at the University of Pittsburgh. Laryngoscope. 2012 Mar; 122(3): 539-42. doi: 10.1002/lary.22406. Epub 2011 Dec 19. PMID: 22183711. NIHMS383093. PMCID: PMC3391608.

Egloff AM, Lui X, Gaither Davis AL, Trevelline BK, Vuga MM, Siegfried JM, Grandis JR. Elevated Gastrin-Releasing Peptide Receptor mRNA expression in buccal mucosa: Association with head and neck Squamous cell carcinoma. Head & Neck. 2012 Mar 20. DOI: 10.1002/hed.22963. [Epub ahead of print]. PMID: 22431275. PMCID: PMC3553276.

Egloff AM, Davis AG, Shuai Y, Land S, Pilewski JM, Luketich JD, Landreneau R, Miller YE, Grandis JR, Siegfried JM. Gastrin-Releasing Peptide Receptor Expression in Non-Cancerous Bronchial Epithelia Is Associated with Lung Cancer: a Case-Control Study. Respiratory Research. 2012 Feb 1; 13(1): 9. [Epub ahead of print]. doi: 10.1186/1465-9921-13-9. PMID: 22296774. PMCID: PMC3305653.

Klein JD, Christopoulos A, Ahn SM, Gooding WE, Grandis JR, Kim S. Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma. Head & Neck. 2012 Feb 6. doi: 10.1002/hed.21917. {Epub ahead of print]. PMID: 22307735. PMC Journal-In Process.

Wheeler SE, Siwak DR, Chai RL, Lavalle CR, Seethala RR, Wang L, Cieply KM, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clinical Cancer Research. 2012 Feb 20. [Epub ahead of print]. PMID: 22351687. PMCID: PMC3430124 [Available on 2013/4/15].

Wheeler SA, Morariu E, Bednash J, Seethala RR, Chiosea SI, Grandis JR. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clinical Cancer Research. 2012 May 15; 18(10): 2850-60. Epub 2012 Apr 6. PMID: 22490227. PMCID: PMC3433855 [Available on 2013/5/15].

Bhola N, Sahu A, Freilini M, Cassell A, Chen CS, Grandis JR. Anti-tumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Molecular Cancer Therapeutics. 2012 May 23. [Epub ahead of print]. PMID: 22491800. PMCID: PMC3413198 [Available on 2013/6/1].

Lui VWY, Grandis JR. Primary chemotherapy and radiation as a treatment strategy for HPV-positive oropharyngeal cancer. Head and Neck Pathology, 2012. Epub 2012 Jul 3. PMID: 22782228. PMCID: PMC3394163 [Available on 2013/7/3].

48. Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, Rock JR, Harfe BD, Henson BJ, Kunzelmann K, Schreiber R, Seethala RR, Egloff AM, Chen X, Lui VW, Grandis JR, Gollin SM. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Research, 2012 Jul 1; 72(13): 3270-81. doi: 10.1158/0008-5472.CAN-12-0475-T. Epub 2012 May 7. PMID: 22564524. NIHMSID: 473634. PMC Journal-in process.

Quesnelle KM, Wheeler SA, Ratay M, Grandis JR. Preclinical Modeling of EGFR Inhibitor Resistance in Head and Neck Cancer. Cancer Biology & Therapy, 2012 Aug; 13(10): 1-11. PMID: 22785204. PMCID: PMC3414414 [Available 2013/8/1].

Moskowitz H, Gooding WE, Thomas SM, Freilino ML, Argiris E, Gross N, Grandis JR, Ferris R. Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer. Oral Oncology. 2012 Jun 23. [Epub ahead of print]. PMID: 22732263. PMCID: PMC3462892 [Available on 2013/12/23].

Sen M, Thomas SM, Kim, SW, Yeh JI, Ferris RL, Johnson JT, Duvvuri U, Lee JA, Sahu N, Joyce S, Freilino ML, Shi H, Li C, Ly D, Rapireddy S, Etter JP, Li PK, Wang L, Chiosea S, Seethala RR, Gooding WE, Chen X, Kaminski N, Pandit K, Johnson DE, Grandis JR. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discovery. 2012 Aug; 2(8): 694-705. 10.1158/2159-8290.CD-12-0191. Epub 2012 Jun 20. PMID: 22719020. NIHMSID: 468365. PMC Journal-in process.

Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harrari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 2013 Jan; 24(1): 220-5. doi: 10.1093/annonc/mds245. Epub 2012 Aug 16. PMID: 22898037. PMCID: PMC3525135.

Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to notch targeting as cancer therapy. Clinical Cancer Research, 2012 Jul 6. [Epub ahead of print]. PMID: 22773520. PMCID: PMC3463728 [Available on 2013/10/1].

Sen M, Joyce S, Panahandeh MC, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting STAT3 abrogates EGFR inhibitor resistance in cancer. Clinical Cancer Research. 2012 Aug 13. [Epub ahead of print]. PMID: 22825581. PMCID: PMC3445706 [Available on 2013/9/15].

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clinical Cancer Research. 2012 Oct 15; 18(20): 5639-49. doi: 10.1158/1078-0432.CCR-12-1213. Epub 2012 Aug 28. PMID: 22929803. PMCID: PMC3473099 [Available on 2013/10/15].

Fung C, Chen X, Grandis JR, Duvvuri U. EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer Biology & Therapy. 2012 Sep 6; 13(14). Epub ahead of print. PMID: 22954701. PMCID: PMC3542232 [Available on 2013/12/1].

Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino M, DeLancey HM, Grandis JR, Li C, Johnson DE. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4. Autophagy. 2012 Sep 20; 8(20). [Epub ahead of print]. PMID: 22995770. PMCID: PMC3541310 [Available on 2013/12/1].

Cassell A, Freilino ML, Thomas, SM, Lee J, Barr S, Panahandeh MC, Grandis JR. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia. 2012 Nov: 14(11): 1005-14. PMID: 23226094. PMCID: PMC3514742.

Sen SM, Grandis JR. Nucleic acid-based approaches to STAT inhibition. JAK-STAT. In press, 2013.

Mason NS, Lopresti BJ, Ruszliewicz J, Dong X, Joyce S, Leef G, Sen M, Wahed AS, Mathis CA, Grandis JR, Thomas M. Utility of 3'-[18F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. American Journals of Nuclear Medicine and Molecular Imaging. In press, 2013.

Thomas SM, Sahu B, Rapireddy S, Bahal R, Wheeler SE, Procopio EM, Kim J, Joyce SJ, Contrucci S, Wang Y, Chiosea SI, Lathrap KL, Watkins S, Grandis JR, Armitage BA, Ly DH. Antitumor effects of EGFR antisense guanidine-based peptide nucleic acids in cancer models. ACS Chemical Biology. 2012 Nov 9. [Epub ahead of print]. PMID: 23113581. NIHMSID: 473640. PMC Journal-in process.

Stabile L, He G, Lui V, Thomas SM, Henry C, Gubish C, Joyce S, Quesnelle K, Siegfried J, Grandis JR. c-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met. Clinical Cancer Research. 2012 Dec 4. [Epub ahead of print]. PMID: 23213056. PMCID: PMC3549019. [Available on 2014/1/15].

Shin DM, Zhang H, Saba N, Chen A, Nannapaneni S, Amin AR, Muller S, Lewis M, Sica G, Kono S, Brandes JC, Grist W, Moreno-Williams R, Beitler JJ, Thomas SM, Chen Z, Shin HJ, Grandis JR, Khuri FR, Chen ZG. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clinical Cancer Research. In press, 2013.

Romick-Rosendale LE, Lui VW, Grandis JR, Wells SI. The fanconi anemia pathway: repairing the link between DNA damaged and squamous cell carcinoma. Mutation Research. 2013 Jan 17. pii: S0027-5107(13)00002-X. doi: 10.1016/j.mrfmmm.2013.01.001. [Epub ahead of print]. PMID: 23333482. NIHMSID: 473647. PMC Journal-in process.

Troy JD, Weissfeld JL, Youk AO, Thomas SM, Wang L, Grandis JR. Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma. Head and Neck Pathology. In press, 2013. NIHMSID: 475990. PMCID: publisher provided directly to PMC.

Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, Grandis JR. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiology. 2013 Mar 20. pii: S1877-7821(13)00032-5. doi: 10.1016/j.canep.2013.02.009. [Epub ahead of print]. PMID: 23523331. NIHMSID: 474615. PMC Journal-in process.

Pendleton K, Grandis JR. Recurrent and/or metastatic squamous cell cancer of the head and neck in patients receiving cisplatin-based chemoradiation: what are the treatment options? Clinical Medicine Insights: Therapeutics. In press, 2013.

Troy TD, Grandis JR, Youk AO, Diergaarde B, Romkes M, Weissfeld JL. Childhood Passive Smoke Exposure is Associated With Adult Head and Neck Cancer. Cancer Epidemiology. In press, 2013. NIHMSID: 471568. PMC Journal-in process.

Lui VW, Hedberg ML, Li H, Vangara B, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert B, Freilino M, Sauerwein S, Peyser N, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala RR, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Ng P, Garraway L, Hammerman P, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discovery. Epub 2013 Apr 26. PMID: 23619167. PMCID: PMC Journal-in process.